chronic wound News
-
Dr. Mike Griffiths, President and CEO of Advanced Oxygen Therapy, Inc makes the cover of Healthcare Insights.
Dr. Mike Griffiths, President and CEO of Advanced Oxygen Therapy, Inc makes the cover of Healthcare Insights. The cover story, “Advanced Oxygen Therapy, Inc: Dedicated To Resolving Acute And Chronic Wounds Through Its Unique Multi-Modality TWO2 therapy,” details the company’s mission as it fights to help patients with chronic wounds. Read More ...
-
Aurealis Therapeutics Publishes First Study on Four-in-One-Combination Therapy Using Live Lactococcus Lactis Expressing Three Human Therapeutic Proteins for the Treatment of Chronic Non-Healing Wounds
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today the publication of the first study on its investigational product AUP-16, a four-in-one -combination therapy using live Lactococcus lactis expressing three human therapeutic proteins for the treatment of chronic non-healing wounds. This announcement comes as the ...
-
Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic ...
-
Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world’s broadest portfolios of affordable, ...
By healiva SA
-
Advanced Oxygen Therapy Inc. Named Among the 10 Most Innovative MedTech Solution Providers to Watch in 2021
Advanced Oxygen Therapy Inc. (AOTI) announced today that it had been named among the 10 Most Innovative MedTech Solution Providers to Watch in 2021 by the journal The Healthcare Insights and is highlighted as the cover story of its May 2021 print edition. The article ...
-
Hybrisan install new electrospinning production line
Hybrisan, the South Wales based advanced antimicrobial specialists, have installed a new Elmarco electrospinning production line to increase the production of PPE equipment, while also accelerating product development to expand its business offering. The equipment is the first of its kind in the UK and forms part of a recent investment to aid the fight against COVID 19, using venture capital ...
-
Expansion of Topical Wound Oxygen (TWO2) Product Family Extends Treatment to Chronic Wound Patients with Larger Limbs, Venous and Diabetic Foot Ulcers
AOTI Inc. announced today an eagerly anticipated expansion of its unique multi-modality Topical Wound Oxygen (TWO2) therapy product family. The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds. Especially ...
-
Aurealis Therapeutics to Strengthen Its Management Team by Appointing Dr. Laurent Décory as Chief Operating Officer
Aurealis Therapeutics, a synthetic biology company developing ground-breaking four-in-one cell and gene therapies, announced today that Mr. Laurent Décory, who joined the Board of Directors in June 2020, has accepted to join the company management team as Chief Operating Officer. Laurent will be in charge of Business Development, Health Economics, Marketing & Communication and ...
-
Microlyte SURGICAL Associated with Positive Outcomes in Prospective Clinical Case Series in Patients at Risk for Surgical Site Infection
Imbed Biosciences, Inc. (Imbed), a privately held biotech company emerging as a leader in advanced wound care, announced today the results of a prospective clinical evaluation of its next-generation wound Matrix, Microlyte® SURGICAL, in diabetic patients undergoing foot and ankle surgery who would ordinarily be at risk of a surgical site infection. Results will be published in the October ...
-
Aurealis Therapeutics Developing a Drug Therapy with Multiple Active Substances in One Product Has Initiated Repeated Dosing Groups in the Diabetic Foot Ulcer Patient Trial
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company, is making a difference in chronic, non-healing wounds by developing a therapy with multiple active substances in one product that are hitting all key pathomechanisms. Chronic wound care needs curative drugs with true active pharmaceutical substances, not just incrementally improved dressings and devices. The company ...
-
Topical Wound Oxygen (TWO2) therapy Treats High-Risk Patients Safely at Home during the COVID-19 Pandemic
AOTI Inc. announced today that since the outbreak of the COVID-19 pandemic it has been focusing all its resources on supporting a growing number of wound care patients being treated at home by its unique multi-modality Topical Wound Oxygen (TWO2) therapy. TWO2 therapy offers a solution that is unique to the wound care space. Once ordered by the prescriber and set-up by our care team, it is ...
-
Aurealis Therapeutics to Strengthen Its Board of Directors by Appointing Dr. Laurent Décory, an Experienced Advanced Wound Care Industry Executive
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the four-in-one biologic drug for chronic non-healing wounds and regenerative diseases, announced today that Mr. Laurent Décory has joined the Board of Directors of the company as of June 10th, 2020. Existing Board Directors Iain Buchanan, Silvio Inderbitzin and Roger Meier were elected to continue ...
-
Microbion Corporation today announced that the company will present a poster highlighting the in vitro activity of pravibismane against M. avium and M. abscessus non-tuberculous mycobacteria (NTM) at the Colorado Mycobacteria Conference 2022: Focus on NTM
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,207,288 to Microbion on December 28, 2021, with claims to the use of Microbion’s proprietary pravibismane topical composition for diabetic foot infections (“DFI”). The patent, entitled “Bismuth-thiol compositions and methods for treating wounds,” ...
-
Microbion Corporation Announces Data Highlighting Pravibismane’s Effect on Bacterial Energetics Presented at ASM Microbe 2022
Microbion Corporation today announced that the company presented a poster highlighting the effect of pravibismane on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Mycobacterium avium species at ASM Microbe 2022 in Washington, DC. The objectives of these studies were to further understand the mechanism of action of pravibismane, in both planktonic and ...
-
Aurealis Pharma Announces 7.8MCHF Financing to Advance the Chronic Wound Lead Candidate AUP-16 to Diabetic Foot Ulcer Patients under New Brand Aurealis Therapeutics AG
Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The Company also confirmed the de-merger and a plan to develop and commercialize the AUP-16 ...
-
Next Science and 3M Donate $300,000 of Breakthrough Wound Treatment to Jacksonville-Area Charities
Next Science (ASX:NXS), an innovative medical technology company that is the leader in treating biofilm-based infections in humans, announced today that it has donated $300,000 worth of BlastX™ Antimicrobial Wound Gel to The Save A Leg, Save A Life Foundation in Ponte Vedra. The donation will support the foundation’s mission of reducing lower extremity amputations and improving wound ...
-
TissueTech Grows Sales Force to Support Footprint Expansion
TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue allografts to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, announced today that they had completed a new round of hiring for their two commercial subsidiaries Bio-Tissue and Amniox Medical. The recently hired sales representatives and associate sales ...
-
Imbed’s Microlyte Matrix Added to VA’S IDIQ Contract
Imbed Biosciences Inc. (Imbed), a developer of next-generation therapies for tissue repair, and Spartan Medical, a veteran-owned Federal Contractor with fourteen years of flawless performance, jointly announced today that Imbed’s Microlyte® Matrix wound dressing portfolio has been added to Spartan Medical’s VA IDIQ Contract with the U.S. Department of Veteran Affairs (VA). The ...
-
TissueTech Announces Rebranding, Adopts BioTissue Name Across Entire Business
TissueTech, Inc.—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions—has unveiled a corporate rebranding, including a name change and a new logo. BioTissue, Inc. and Amniox Medical, Inc. will now both be known under a single commercial, customer facing entity, ...
-
Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors
VALENCIA, Calif. and MELBOURNE, Australia, April 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that Louis Drapeau has resigned, effective April 29, 2022, from the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you